Association of dual SGLT-2 inhibitor and GLP-1 receptor agonist therapy with colon cancer risk in post-polypectomy patients with diabetes: a target trial emulation - PubMed
5 hours ago
- #diabetes-therapy
- #chemoprevention
- #colon-cancer
- The study examined the association between dual SGLT-2 inhibitor and GLP-1 receptor agonist therapy and colon cancer risk in post-polypectomy patients with type 2 diabetes using a target trial emulation approach.
- It utilized de-identified patient data from the TriNetX Global Collaborative Network, with ethics approval and waived informed consent due to the retrospective nature.
- The research involved methodologies like propensity score matching and was framed around chemoprevention of colon cancer in this high-risk diabetic population.
- Authors declared no competing interests and noted the use of AI-assisted tools for language refinement during manuscript preparation.